Bellerophon Therapeutics, Inc. (BLPH) Reaches $2.03 After 7.00% Down Move; CURAEGIS TECH (CRGS) Shorts Decreased By 31.58%

January 14, 2018 - By Maria Brooks

CURAEGIS TECH INCORPORATED (OTCMKTS:CRGS) had a decrease of 31.58% in short interest. CRGS’s SI was 2,600 shares in January as released by FINRA. Its down 31.58% from 3,800 shares previously. With 45,600 avg volume, 0 days are for CURAEGIS TECH INCORPORATED (OTCMKTS:CRGS)’s short sellers to cover CRGS’s short positions. The stock increased 4.03% or $0.01 during the last trading session, reaching $0.31. About 10,113 shares traded. CurAegis Technologies, Inc. (OTCMKTS:CRGS) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) is a huge mover today! The stock decreased 4.25% or $0.09 during the last trading session, reaching $2.03. About 148,648 shares traded. Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) has risen 23.81% since January 14, 2017 and is uptrending. It has outperformed by 7.11% the S&P500.The move comes after 6 months negative chart setup for the $112.02M company. It was reported on Jan, 14 by We have $1.89 PT which if reached, will make NASDAQ:BLPH worth $7.84M less.

CurAegis Technologies, Inc. develops and markets advanced technologies in the areas of power, safety, and wellness. The company has market cap of $15.13 million. It focuses on the commercialization of various technologies, including myCadian watch, a wearable device, which is used to predict and detect the degradation of alertness in a user, and reveal sleep and fatigue problems; Z-Coach, an e-learning tool that offers sleep training and education solutions to correct sleep issues and enhance overall wellness; and hydraulic pumps for off road diesel engines. It currently has negative earnings. The firm was formerly known as Torvec, Inc. and changed its name to CurAegis Technologies, Inc. in June 2016.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. The company has market cap of $112.02 million. The Company’s product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.